BioCrossroads

Gate Neurosciences is a healthcare company that offers neuroscience-related medical services. The company is developing the next-generation of targeted CNS therapies, leveraging precision medicine approaches to develop breakthrough drugs for psychiatric and neurologic diseases. It was founded in 2018 and is headquartered in Carmel, IN, USA.

Lumavate, LLC operates a cloud-based software platform that empowers manufacturers to enhance customer experiences through mobile engagement. The platform allows product manufacturers and brands to transform their labels into interactive channels, providing end-users with essential information for product repairs, authentic parts sourcing, and easy access to services and technicians. Catering to a diverse range of industries, Lumavate serves clients in sectors such as infrastructure, outdoor activities, and industrial markets, including healthcare equipment and HVAC systems. The company's enterprise platform is designed for building progressive web apps (PWAs) at scale, enabling companies to deliver personalized mobile experiences that drive user engagement and adoption throughout the customer journey. Founded in 2015 and based in Carmel, Indiana, Lumavate was previously known as LabelNexus, LLC before rebranding in July 2015.

Kovina Therapeutics is a pre-clinical biotechnology company focused on developing non-surgical medical treatments for Human Papillomavirus (HPV) infections and related cancers. The company is dedicated to discovering antiviral therapeutics that utilize drug-like compounds to target and inactivate a crucial HPV protein commonly expressed in early, pre-malignant, and cancerous conditions. By doing so, Kovina Therapeutics aims to provide effective treatment options for medical practitioners to address HPV-related health issues, ultimately improving patient outcomes in the fight against these infections and malignancies.

Novosteo Inc., founded in 2017 and located in West Lafayette, Indiana, focuses on developing and manufacturing innovative drugs aimed at treating bone injuries and diseases. The company addresses significant health issues related to bone fractures, including morbidity, mortality, and reduced mobility and productivity. Its scientific co-founders from Purdue University have pioneered a proprietary chemistry approach that targets bone regeneration. Novosteo's drug discovery platform features a range of fracture-targeted therapeutics designed to deliver healing agents directly to fracture sites, enhancing the healing process and alleviating the debilitating effects associated with bone injuries. Through its novel biologics, Novosteo aims to improve patient outcomes and quality of life.

Sabanto specializes in Farming-as-a-Service, focusing on enhancing autonomy in agricultural operations through innovative technology. The company offers low-cost retrofits for existing agricultural machinery, regardless of the make or model, enabling farmers to modernize their equipment affordably. Additionally, Sabanto develops supporting software that enhances the utility of autonomous technologies, ultimately improving return on investment for producers. By providing a supervised autonomous equipment platform, Sabanto delivers comprehensive agriculture services that allow farmers to monitor and manage their farmlands efficiently from a centralized location. This approach not only streamlines operations but also advances the future of agriculture through accessible and effective technological solutions.

MBX Biosciences, Inc. is a biotechnology company based in Carmel, Indiana, specializing in the development of therapeutics for rare endocrine disorders. Established in 2018, the company focuses on creating peptides aimed at treating genetic diseases that affect glandular hormones, which play a crucial role in the body’s chemical messaging system. By targeting conditions with inadequate treatment options, MBX Biosciences is dedicated to discovering, developing, and commercializing innovative endocrine therapeutics.

Sexton Biotechnologies announced today that it has raised $5 million in growth capital and is the first company incubated by Indianapolis-based Cook Regentec to secure outside investment capital and spin out as an independent biotechnology company. In addition to ongoing research and product development, Sexton Biotechnologies will expand and scale commercialization of its portfolio of container closure and media supplementation tools for cell and gene therapy bioproduction.

Sabanto specializes in Farming-as-a-Service, focusing on enhancing autonomy in agricultural operations through innovative technology. The company offers low-cost retrofits for existing agricultural machinery, regardless of the make or model, enabling farmers to modernize their equipment affordably. Additionally, Sabanto develops supporting software that enhances the utility of autonomous technologies, ultimately improving return on investment for producers. By providing a supervised autonomous equipment platform, Sabanto delivers comprehensive agriculture services that allow farmers to monitor and manage their farmlands efficiently from a centralized location. This approach not only streamlines operations but also advances the future of agriculture through accessible and effective technological solutions.

Lumavate, LLC operates a cloud-based software platform that empowers manufacturers to enhance customer experiences through mobile engagement. The platform allows product manufacturers and brands to transform their labels into interactive channels, providing end-users with essential information for product repairs, authentic parts sourcing, and easy access to services and technicians. Catering to a diverse range of industries, Lumavate serves clients in sectors such as infrastructure, outdoor activities, and industrial markets, including healthcare equipment and HVAC systems. The company's enterprise platform is designed for building progressive web apps (PWAs) at scale, enabling companies to deliver personalized mobile experiences that drive user engagement and adoption throughout the customer journey. Founded in 2015 and based in Carmel, Indiana, Lumavate was previously known as LabelNexus, LLC before rebranding in July 2015.

OmniVis is a biotechnology company that has created an integrated portable platform for the detection of pathogens in various environments, including food processing facilities. The company offers a handheld device that quantitatively measures pathogens, providing accurate results in under 30 minutes. This technology utilizes single-use disposable test kits that analyze swabs or liquid samples, significantly reducing the time and labor associated with traditional lab testing. By delivering a low-cost and user-friendly solution, OmniVis enables health organizations to enhance their pathogen detection capabilities effectively.

Allinaire Therapeutics, LLC is a biotechnology company based in Cleveland, Ohio, founded in 2015. The company focuses on developing innovative therapeutics for chronic obstructive pulmonary disease (COPD) and other pulmonary diseases. Its research is grounded in the discovery of a novel therapeutic target identified by its scientific founders, Irina Petrache, MD, and Matthias Clauss, Ph.D. This target is significant in the understanding and treatment of lung diseases, including pulmonary arterial hypertension (PAH). By targeting this mechanism, Allinaire Therapeutics aims to provide new treatment options that could improve clinical outcomes for patients suffering from various cardiopulmonary conditions.

Scioto Biosciences is a developer of Activated Bacterial Therapeutics (ABT) platform intended to deliver live bacteria to the gut. The company is developing innovative therapies devoted to having a transformative impact on the delivery of microbiome therapeutics, enabling medical practitioners to advance healing through microbiome therapeutics.

SpeechVive Inc. is a medical technology company based in Lafayette, Indiana, founded in 2011. It focuses on developing an innovative wearable device aimed at improving communication for individuals with Parkinson's disease. The device enhances speech volume and clarity by reducing background noise, thereby facilitating better hearing and communication for patients. By addressing the specific challenges faced by those with Parkinson's, SpeechVive aims to empower users to lead more normal lives through improved verbal communication.

Calibrium is a privately-held biopharmaceutical company dedicated to the development of innovative drug candidates aimed at treating diabetes and related metabolic disorders. Co-founded by Fritz French, who serves as Chief Executive Officer, and Richard DiMarchi, PhD, the Chief Scientific Officer, Calibrium focuses on creating a diverse portfolio of therapeutic solutions to address the growing challenges posed by these conditions.

Assembly Pharmaceuticals is a virology-focused biopharmaceutical company with a discovery platform and programs based on proprietary Core Protein Allosteric Modulators (CpAMs) for the treatment of viral infections, starting with hepatitis B (HBV). CpAMs can alter the activities of the HBV core protein, a unique viral protein with no human analogue that is involved in multiple stages of the HBV life cycle. In contrast to current therapies that only suppress HBV, Assembly Pharmaceutical’s CpAMs may have curative potential by eliminating the viral reservoir in infected individuals. Hepatitis B infection has a worldwide prevalence of over 350 million and more than 600,000 people die every year from complications associated with chronic HBV. Assembly has operations in Indiana and San Francisco.

Diagnotes, Inc. is a digital healthcare company based in Indianapolis, Indiana, that specializes in enhancing communication and collaboration within the healthcare industry. Established in 2010, the company offers a clinical communication platform designed to facilitate secure messaging, provider scheduling, patient data management, and documentation of discussions. This platform is tailored to the needs of various stakeholders, including patients, physicians, care teams, hospitals, health systems, and physician practices, enabling them to efficiently manage all patient-related communications. Diagnotes' applications are intuitive and easily adopted, serving a diverse clientele that includes large health systems, community hospitals, long-term care facilities, and behavioral health organizations. The platform supports a range of functionalities, from simple messaging to telehealth consultations, ensuring effective communication among healthcare professionals and their patients on a unified, cloud-based system.

Bioscience Vaccines is a life-science company with proprietary adjuvant technology referred to as Matrix Immune Modulator and is based in the Purdue Research Park in West Lafayette, Ind. The company's products originated in the laboratory of Dr. Mark Suckow of the University of Notre Dame and are based on a technology discovered at Purdue University. The company's technology has the potential to be formulated as a companion product with vaccine products already approved and marketed for use by the FDA for the prevention of specific human and animal diseases.

ImmuneWorks develops immune tolerance treatments for patients with serious autoimmune diseases in the lung. The company was founded in 2006 to develop safe and effective immune tolerance treatments for patients with serious autoimmune diseases of the lung. The scientific foundation of the company is ImmuneWorks' groundbreaking discovery that antigen-specific autoimmunity is responsible for the disease in over one-half of idiopathic pulmonary fibrosis (IPF) patients. It was incorporated in 2006 and is based in Indianapolis, Indiana.

FlowCo is a medical device company developing products to improve the flow of blood through the vascular system.

CS-Keys is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer.